Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Akebia Therapeutics

Evaluate

Thumbnail
April 04, 2022

US FDA approval tracker: March 2022

Thumbnail
March 31, 2022

Akebia’s vadadustat knockback increases class doubts

Article image
Vantage logo
February 25, 2022

Go or no go? Bristol’s Lag3 debut

March Pdufa dates are set for relatlimab as well as Akebia’s vadadustat, while Amylyx’s ALS drug heads for a panel.

Article image
Vantage logo
December 10, 2021

Another bust for Vifor and Angion

Article image
Vantage logo
November 22, 2021

Vifor plumps for a double acquisition

Article image
Vantage logo
November 08, 2021

ASN 2021 – Glaxo’s daprodustat delivers

But whether data on the novel anaemia pill are clean enough to dispel wider FDA toxicity concerns is hard to call.

Article image
Vantage logo
October 27, 2021

Angion’s kidney transplant dream dies

The group will have to pivot to a heart surgery setting, but the omens here are not good. Meanwhile, Vifor’s run of bad luck continues.

Article image
Vantage logo
September 14, 2021

Astellas readies roxadustat for launch

But winning EU approval for the novel anaemia pill was not straightforward, the Japanese firm says.

Article image
Vantage logo
June 25, 2021

EU thumbs up for roxadustat, but US panel approaches

Article image
Vantage logo
June 23, 2021

New Glaxo: it’s all about the late-stage assets

Walmsley wins some breathing space but, for ambitious new growth targets to be met, the pipeline must start delivering.

Article image
Vantage logo
April 08, 2021

Hopes fade for novel anaemia pills, but could Glaxo yet prevail?

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up